Skip to content

Strand Therapeutics

7 viewers · 30d

Total raised

$108.1M

1 filing since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $108.1M
ROUNDS
1
INVESTORS
10
FOUNDED
N/A
HQ
Boston, MA
SECTOR
Biotechnology
EMPLOYEES
N/A
30D VIEWERS
7

AI overview

Updated

Strand Therapeutics is a clinical-stage biotechnology company developing programmable mRNA therapeutics to treat cancer and other life-threatening diseases. Founded by biological engineers from MIT, the company aims to create autonomous medicines that can precisely target diseased cells and deliver multi-functional treatments. The core technology is based on the first mRNA programming language, designed to improve therapeutic outcomes.

What sets it apart

The company's innovation lies in its intelligent, tumor-targeted mRNA platform that enables the creation of programmable drugs. These drugs can act specifically at the site of disease, which could offer a more precise and effective alternative to systemic treatments.

Funding history

1 round
EquityMay 23, 2025
Form D
+$108.1M$108.1M total

Latest SEC filings

via EDGAR · CIK 0001778475
Form D · May 23, 2025View on EDGAR

Products

1 tracked

STX-001

Cancer Immunotherapy

STX-001 is a programmable mRNA therapy candidate designed for the treatment of solid tumors. It utilizes a multi-modal synthetic self-replicating mRNA technology to deliver a prolonged and locally-acting IL-12 cytokine directly into the tumor microenvironment. The therapy has received Investigational New Drug (IND) clearance from the FDA and is currently in Phase 1 clinical trials.

  • Programmable, self-replicating mRNA technology
  • Localized delivery of IL-12 cytokine
  • Targeting of the tumor microenvironment
  • Designed for treatment of solid tumors

Links

WebsiteSEC EDGAR filings